Visualizing the Conversion Process of Alcohol-Induced Fatty Liver to Steatohepatitis in Vivo with a Fluorescent Nanoprobe

Excess alcohol consumption and the associated development of alcoholic liver disease (ALD) are major public health challenges worldwide. Since patients with the severe stages of ALD no longer benefit from clinical therapies, early warning of ALD holds significant promise for increasing the cure rate of ALD. Herein, we develop a bicolor fluorescent nanoprobe for dynamically monitoring the conversion process of alcohol-induced fatty liver to steatohepatitis in vivo through simultaneous imaging of microRNA 155 and osteopontin mRNA, which are related to fatty liver and steatohepatitis, respectively. The fluorescence imaging results indicate that the nanoprobe can effectively differentiate alcohol-induced fatty liver and steatohepatitis. Moreover, the nanoprobe can monitor the transmutation process of alcohol-induced fatty liver to steatohepatitis and assess the remission effects of N-acetyl cysteine for alcohol-induced liver injury. We anticipate the developed nanoprobe and imaging method can provide new ways for early warning, treatments, and prognosis of ALD.